EUS-guided coil and glue vs glue injection for bleeding gastric varices in cirrhosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized, open-label study compares two endoscopic treatments for bleeding gastric varices in patients with cirrhosis. Participants are assigned 1:1 to receive either EUS-guided coil deployment with cyanoacrylate glue or conventional cyanoacrylate glue injection alone. The primary outcome is all-cause rebleeding within 12 months, with secondary outcomes including technical success and timing of any rebleeding. The trial plans to enroll 158 participants across tertiary centers. The approach leverages EUS to visualize varices and feeding vessels to improve obliteration and potentially reduce complications.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age \> 18 years
* Confirmed diagnosis of liver cirrhosis with portal hypertension
* Patients presenting with suspected bleed from cardio-fundal varices, specifically classified as gastroesophageal varices type-2 (GOV-2) or isolated gastric varices type-1 (IGV-1)

Exclusion Criteria:

* Patients experiencing bleeding from esophageal varices (EV) or gastroesophageal varices type-1 (GOV-1) or IGV2
* Patients with non-cirrhotic portal hypertension
* Active spurt of blood noted from gastric varices seen on endoscopy
* Pregnancy
* Patients with refractory shock
* Sepsis/ACLF
* Platelet count \< 50,000 /mL and International Normalized Rate (INR) \> 2.0
* Contraindication to endoscopy
* Not willing to provide consent

Where it's running

• Medanta The Medicity
  Gurgaon, Haryana, India Recruiting
• Orlando Health Orlando Regional Medical Center
  Orlando, Florida, United States Not yet recruiting

Study contacts

• Study coordinator: Rajesh Puri, MD
• Email: purirajesh1969@gmail.com
• Phone: +919999411125

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Endovascular treatment outcomes after portal hypertension–related GI bleeding in cirrhosis

  This study tests how well endovascular procedures for portal hypertension–related GI bleeding work in adults with cirrhosis, and what factors predict outcomes.

  Recruiting University Medical Center Ho Chi Minh City (UMC) · Ho Chi Minh City · NCT07918378

• 4D-Flow MRI to see portal hypertension and TIPS outcomes in cirrhosis

  This study tests a noninvasive 4D-Flow MRI method to see if it can safely and reliably reflect portal hypertension and predict outcomes for people with cirrhosis, including those needing a TIPS procedure.

  Recruiting at 2 sites Assistance Publique - Hôpitaux de Paris · Paris and 1 other locations · NCT07554183

• Apixaban plus carvedilol to prevent portal-hypertension complications in cirrhosis

  This will test whether adding apixaban to carvedilol can help prevent variceal bleeding, portal vein thrombosis, and other portal-hypertension complications in adults with Child-Pugh B cirrhosis.

  Recruiting Phase 4 Asian Institute Of Medical Sciences · Hyderābād, Sindh · NCT07521332

• Factors that affect reopening of blocked portal veins in people with cirrhosis and gastroesophageal varices

  This project looks at past records and follow-up to see which factors are linked with reopening (recanalization) of blocked portal veins in people who have cirrhosis and endoscopy-confirmed gastroesophageal varices.

  Recruiting Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT07473375

• Copper supplementation for people with cirrhosis

  This trial will try giving copper supplements to adults with cirrhosis who have low copper levels or signs of copper deficiency to see if liver-related health improves.

  Recruiting University of Washington · Seattle, Washington · NCT07471542

• Biannual liver cancer screening with ultrasound and AFP for compensated non‑viral cirrhosis in Central Denmark

  This program will try giving people aged 40–79 with compensated non‑viral cirrhosis ultrasound scans plus AFP blood tests every six months to see if screening lowers deaths from liver cancer.

  Recruiting at 6 sites University of Aarhus · Aarhus, Central Jutland and 5 other locations · NCT07469319

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.